The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations Academic Article uri icon


  • Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.

publication date

  • July 3, 2014